Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.46
    +2.34 (+0.31%)
     

  • GBP/EUR

    1.1668
    +0.0011 (+0.10%)
     

  • GBP/USD

    1.2470
    -0.0041 (-0.33%)
     

  • Bitcoin GBP

    50,934.10
    -368.75 (-0.72%)
     

  • CMC Crypto 200

    1,319.08
    -77.45 (-5.54%)
     

  • S&P 500

    5,101.99
    +53.57 (+1.06%)
     

  • DOW

    38,236.82
    +151.02 (+0.40%)
     

  • CRUDE OIL

    83.99
    +0.42 (+0.50%)
     

  • GOLD FUTURES

    2,348.10
    +5.60 (+0.24%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

PTC Therapeutics (PTCT) Soars 5.8%: Is Further Upside Left in the Stock?

Zacks Equity Research
·2-min read

PTC Therapeutics (PTCT) shares rallied 5.8% in the last trading session to close at $41.60. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.1% gain over the past four weeks.

The stock rallied after the company reported robust preliminary net revenues as well as net product revenues for full year 2022 at the J.P. Morgan Healthcare Conference on Jan 9. The company also provided strong guidance for total revenues for full year 2023 at the conference. This is also a positive.

This biopharmaceutical company is expected to post quarterly loss of $1.61 per share in its upcoming report, which represents a year-over-year change of +20.7%. Revenues are expected to be $195.3 million, up 18.2% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

ADVERTISEMENT

For PTC Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on PTCT going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

PTC Therapeutics belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Esperion Therapeutics (ESPR), closed the last trading session 11% higher at $6.99. Over the past month, ESPR has returned 23.8%.

For Esperion Therapeutics , the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.87. This represents a change of +50.9% from what the company reported a year ago. Esperion Therapeutics currently has a Zacks Rank of #3 (Hold).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

PTC Therapeutics, Inc. (PTCT) : Free Stock Analysis Report

Esperion Therapeutics, Inc. (ESPR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research